Sonoma Biotherapeutics has taken over three of four floors in a building formerly occupied by the tech company F5, spanning a total of 83,000 square feet. The new lab space is large enough for roughly 65 scientists, who are working on early-state research that precede clinical trials. It’s pursuing treatments that use what are known as regulatory T (Treg) cells to protect the cells under attack.